RemeGen (HKG:9995, SHA:688331) posted a profit attributable to owners of 709.7 million yuan for 2025, from a loss of 1.47 billion yuan a year earlier, according to a March 27 Hong Kong bourse filing.
The biopharmaceutical company's Hong Kong shares were up nearly 6% in Monday's afternoon trade.
Earnings per share came in at 1.29 yuan, compared with a loss per share of 2.73 yuan a year earlier.
Revenue rose to 3.24 billion yuan from 1.71 billion yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments